Q3 2024 Earnings Forecast for Immunic, Inc. Issued By B. Riley (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at B. Riley issued their Q3 2024 EPS estimates for Immunic in a research report issued on Monday, August 26th. B. Riley analyst W. Wood forecasts that the company will earn ($0.23) per share for the quarter. B. Riley has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q4 2024 earnings at ($0.24) EPS, FY2025 earnings at ($0.56) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.14) EPS.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. During the same period last year, the company posted ($0.54) EPS.

Several other analysts also recently issued reports on the company. Piper Sandler restated an “overweight” rating and set a $28.00 price objective on shares of Immunic in a report on Tuesday, July 16th. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Immunic Stock Up 1.3 %

Shares of NASDAQ IMUX opened at $1.51 on Thursday. Immunic has a 12 month low of $0.95 and a 12 month high of $1.92. The company has a market cap of $136.02 million, a price-to-earnings ratio of -0.83 and a beta of 1.76. The business has a fifty day simple moving average of $1.32 and a 200-day simple moving average of $1.30.

Institutional Investors Weigh In On Immunic

Several hedge funds have recently bought and sold shares of the business. BVF Inc. IL purchased a new stake in shares of Immunic in the first quarter worth approximately $11,752,000. Janus Henderson Group PLC acquired a new stake in shares of Immunic during the 1st quarter valued at $9,266,000. Vanguard Group Inc. grew its holdings in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after acquiring an additional 1,703,047 shares in the last quarter. Ikarian Capital LLC increased its stake in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Finally, Sierra Summit Advisors LLC purchased a new stake in shares of Immunic during the fourth quarter worth $487,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.